Dosage Forms

Articles

AstraZeneca's CEO David Brennan To Retire; PRA, Amgen Reach New Biosimilar Agreement; and More.

Week of Apr. 30, 2012: AstraZeneca's CEO David Brennan to Retire; PRA, Amgen Reach New Biosimilar Agreement; and More

Amy Ritter was Scientific Editor, BioPharm International.

Ranbaxy Laboratories announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer's Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.

Ranbaxy Begins Shipping Generic Lipitor From Indian Facility

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.

GPhA Urges Congress to Move Ahead on Generic-Drug and Biosimilar User Fees

AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More.

Week of Mar. 12, 2012: AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More

BASi Restructures; Celerion, Ricerca Biosciences Form Biosimilars Alliance; and More.

Week of Mar. 5, 2012: BASi Restructures; Celerion, Ricerca Biosciences Form Biosimilars Alliance; and More

The Bulk Pharmaceuticals Task Force, an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), issued its support for the introduction of a House bill, the Generic Drug and Biosimilar User Fee Act (HR 3988), which SOCMA says will help to achieve parity between foreign and domestic firms.

SOCMA Issues Support for Generic-Drug User Fees

SOCMA's Bulk Pharmaceuticals Task Force outlines key goals and challenges for user-fee legislation.

Generic Drug User Fees Mark a Step in the Right Direction

Angie Drakulich was editorial director of Pharmaceutical Technology.

Has the long-awaited guidance answered all of the industry's questions?

FDA Guides the Way to Biosimilars in the US

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.

News: Market Boom for Generics

JHS Secures Four Sterile Parenteral Products Manufacturing Contracts; Samsung Biologics, Biogen Idec Establish Biosimilars Joint Venture; and More.

Week of Feb. 27, 2012: JHS Secures Four Sterile Parenteral Products Manufacturing Contracts; Samsung Biologics, Biogen Idec Establish Biosimilars Joint Venture; and More

Generic Drugs